Illumina/TruSight Tumor 170 Kit plus Watson for Genomics/20018622/1 Ea
Product Highlights:
TruSight Tumor 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types. The comprehensive nature provides laboratories with a deep view into the genetics of cancer.
- Comprehensive Coverage of Cancer-Related VariantsAssessment of fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications in one assay using DNA and RNA creates efficiencies in sample usage, time, and cost.
- Accurate Results from Low-Quality Samples1Variant detection with as little as 40 ng DNA and RNA input, and as low as 5% mutant allele frequency, maximizes the results from precious formalin-fixed paraffin-embedded (FFPE) samples.
- Integrated, Streamlined WorkflowDNA and RNA are prepared in parallel with an integrated workflow following DNA shearing/cDNA synthesis.
Specifications:
| Assay Time | ~2 days (Library Prep) |
| Hands-On Time | ~10.5 hours |
| Input Quantity | 40 ng DNA and/or RNA |
| Method | Targeted RNA Sequencing,Targeted DNA Sequencing |
| Variant Class | Single Nucleotide Polymorphisms (SNPs),Gene Fusions,Somatic Variants,Structural Variants,Insertions-Deletions (indels),Copy Number Variants (CNVs) |
| Specialized Sample Types | FFPE,Low Input |
| System Compatibility | NextSeq 550,NextSeq 500,HiSeq 2500 |
| Technology | Sequencing |
| Species Category | Human |
| Cancer Type | Solid Tumor |
Scientific Posters:
AACR 2017: TruSight Tumor 170 and Tumor Mutational Burden
Results of analysis indicate that TruSight Tumor 170, with comprehensive coverage of cancer-related genes, shows high concordance with whole exome sequencing for accurate assessment of tumor mutational burden.
Learn More
AACR 2017: TruSight Tumor 170 and Solid Tumor Profiling Analytical Performance with FFPE Samples
Standard extractions from FFPE embedded samples provide sufficient material (40ng) in >95% of samples that were extracted by Illumina. This data shows that the TruSight Tumor 170 panel is a robust assay that generates passing sample QC data in >85%of samples with varying quality, and in >95% of samples that have quality metrics that fall within the recommendations for the kit.
Learn More
AACR 2017: TruSight Tumor 170 for Small Nucleotide Variations and Gene Amplifications in FFPE DNA Samples
TruSight Tumor 170 can achieve high sensitivity and specificity for the detection of somatic variants (small variants and CNVs) from DNA extracted from FFPE tissues.
Learn More
AACR 2017: TruSight Tumor 170 for Fusions and Splice Variants in FFPE RNA Tumor Samples
Through examining limit of detection in the context of RNA expression, this study shows that TruSight Tumor 170 provides high sensitivity and specificity in RNA variant calling down to 5 copies of transcript per ng of input.
Learn More
本文链接： https://www.ebiomall.cn/b45-allele/info-1552448005.html
